Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab-a human anti-programmed death-ligand 1 (PD-L1) monoclonal antibody-showed promising efficacy and a safety profile that was generally manageable and tolerable. Here, we report the efficacy of avelumab after ≥1 year of follow-up in patients with distant mMCC that had progressed following prior chemotherapy for metastatic disease. PATIENTS AND METHODS: Patients received avelumab 10 mg/kg by 1-h intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was best overall response. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). RESULTS: Patients (N = 88) were followed for a minimum of 12 months. The confirmed objective response rate was 33.0% (95% CI, 23.3%-43.8%; complete response: 11.4%). An estimated 74% of responses lasted ≥1 year, and 72.4% of responses were ongoing at data cutoff. Responses were durable, with the median DOR not yet reached (95% CI, 18.0 months-not estimable), and PFS was prolonged; 1-year PFS and OS rates were 30% (95% CI, 21%-41%) and 52% (95% CI, 41%-62%), respectively. Median OS was 12.9 months (95% CI, 7.5-not estimable). Subgroup analyses suggested a higher probability of response in patients receiving fewer prior lines of systemic therapy, with a lower baseline disease burden, and with PD-L1-positive tumors; however, durable responses occurred irrespective of baseline factors, including tumor Merkel cell polyomavirus status. CONCLUSIONS: With longer follow-up, avelumab continues to show durable responses and promising survival outcomes in patients with distant mMCC whose disease had progressed after chemotherapy. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02155647.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Survival outcomes in patients with mMCC receiving avelumab. Kaplan-Meier estimates of (a) progression-free survival (PFS) and (b) overall survival (OS). Vertical lines indicate censored events. Also depicted in (a) are Kaplan-Meier estimates of PFS for recent retrospective studies of second-line (2 L) or second-line and later (2 L+) chemotherapy in patients with mMCC [13–15]. NE, not estimable. a Includes both immunocompetent and immunocompromised patients. All patients progressed; therefore, none were censored. b PFS rate at 6 months was 0%. c One patient with PR had PFS lasting 354 days; 95% of patients receiving second-line chemotherapy had progressed at 230 days](https://figures.cochat.ai/paper-figures/b289238a603144c4b07a19527145d876/updated-efficacy-of-avelumab-in-patients-with-previously-treated-metastatic-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“anti-PD-L1 antibodies such as Atezolizumab, Avelumab, and Durvalumab, have been developed and proven effective for treatment of a variety of cancers including NSCLC, urothelial carcinoma, triple negative breast cancer (TNBC) and Merkel cell carcinoma (Iwata et al., 2019; Kaufman et al., 2018; Powles et al., 2018; Rittmeyer et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Kaufman et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“1 [11], and adequate hematological, hepatic, and renal function.”
BackgroundPD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Self-citationKaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236 · cited 10×
“Efficacy parameter ≥6 months of follow-up [8] ≥1 year of follow-up”
BackgroundMethodResultInfluentialSelf-citationMerkel Cell Carcinoma: Prognosis and Treatment of Patients From a Single Institution
Allen, P. J., Bowne, W. B., Jaques, D. P., Brennan, M. F., Busam, K., & Coit, D. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.329 · Cited by 739 · cited 1×
“Up to 12% of patients with MCC have distant metastatic disease (mMCC), which has a poor prognosis [1, 3], and progression to mMCC is frequent in patients with local or regional disease (up to 21%) [4].”
BackgroundLebbe, C., Becker, J. C., Grob, J.-J., Malvehy, J., del Marmol, V., Pehamberger, H., Peris, K., Saiag, P., Middleton, M. R., Bastholt, L., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.131 · Cited by 500
Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs
Schadendorf, D., Lebbé, C., zur Hausen, A., Avril, M.-F., Hariharan, S., Bharmal, M., & Becker, J. C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.022 · Cited by 397 · cited 1×
“Up to 12% of patients with MCC have distant metastatic disease (mMCC), which has a poor prognosis [1, 3], and progression to mMCC is frequent in patients with local or regional disease (up to 21%) [4].”
BackgroundMerkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
Bichakjian, C. K., Olencki, T., Aasi, S. Z., Alam, M., Andersen, J. S., Blitzblau, R., Bowen, G. M., Contreras, C. M., Daniels, G. A., Decker, R., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0055 · Cited by 319
Iyer, J. G., Blom, A., Doumani, R., Lewis, C., Tarabadkar, E. S., Anderson, A., Ma, C., Bestick, A., Parvathaneni, U., Bhatia, S., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.815 · Cited by 260
Nghiem, P., Kaufman, H. L., Bharmal, M. F., Mahnke, L. A., Phatak, H. M., & Becker, J. C. (2017) · Future Oncology · doi:10.2217/fon-2017-0072 · Cited by 156 · cited 1×
“Although no prospective clinical trials of chemotherapy have been conducted and no regimen has been specifically approved for mMCC treatment, platinum/etoposide combinations have been widely used and achieve relatively high objective response rates (ORRs); response duration, however, is short and no clear survival adv…”
BackgroundTopalian, S. L., Bhatia, S., Hollebecque, A., Awada, A., Boer, J. P. D., Kudchadkar, R. R., Goncalves, A., Delord, J.-P., Martens, U. M., Picazo, J. M. L., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct074 · Cited by 151
Research works printed but not linked: 2
- Bavencio. (avelumab) injection [package insert]. Darmstadt: Merck KGaA; 2017.
- Becker J, Lorenz E, Haas G, Helwig C, Oksen D, Mahnke L, et al. Evaluation of real world treatment outcomes in patients with metastatic Merkel cell carcinoma (MCC) following second line chemotherapy. Ann Oncol 2016;26(Suppl 3 [Abstract 2602]). doi: https://doi.org/10.1158/1538-7445.AM2017-CT074 . · DOI · Paper page
Cited by
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Hiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400
Becker, J. C., Stang, A., DeCaprio, J. A., Cerroni, L., Lebbé, C., Veness, M., & Nghiem, P. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.77 · Cited by 645
Maleki Vareki, S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0479-7 · Cited by 569
“Another example of this phenomenon is the high ORR among Merkel Cell Carcinoma (MCC) patients with Merkel cell polyomavirus (MCPyV) positive tumors in response to treatment with avelumab (an anti-PD-L1 antibody) despite the relatively low mutation burden in this tumor type [14].”
Metadata
- Authors
- Kaufman, H. L., Russell, J. S., Hamid, O., Bhatia, S., Terheyden, P., D’Angelo, S. P., Shih, K. C., Lebbé, C., Milella, M., Brownell, I., Lewis, K. D., Lorch, J. H., von Heydebreck, A., Hennessy, M., & Nghiem, P.
- Affiliations
- Rutgers Cancer Institute (US)
- Moffitt Cancer Center (US)
- Angeles Clinic and Research Institute (US)
- University of Washington Medical Center (US)
- University of Lübeck (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Sarah Cannon Research Institute (GB)
- National Institutes of Health (US)
- University of Colorado Anschutz (US)
- Dana-Farber Cancer Institute (US)
- EMD Serono, Inc. (United States) (US)
- Corresponding author
- Kaufman, Howard L.
- ORCID
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2018-01-19
- Volume
- 6
- Issue
- 1
- Pages
- 7-7
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC5774167
- OpenAlex
- W2783234388
- Cited by
- 334
- References
- 14
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 25 · 2023: 28 · 2022: 21 · 2021: 62 · 2020: 69 · 2019: 71 · 2018: 27
- FWCI
- 21.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Merck KGaA, Darmstadt, Germany
- Pfizer Inc.
- Topics
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- avelumab, Merkel cell carcinoma, metastatic Merkel cell carcinoma, PD-L1 blockade, immune checkpoint inhibitors, long-term follow-up, durable response, progression-free survival, overall survival, Merkel cell polyomavirus, prior chemotherapy, objective response rate, PD-L1 expression, safety and tolerability
- MeSH terms
- Aged, Antibodies, Monoclonal, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Metastasis, Skin Neoplasms, Time Factors, Carcinoma, Merkel Cell, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. https://app.cochat.ai/papers/10.1186/s40425-017-0310-x
- The paper
- Kaufman, H. L., Russell, J. S., Hamid, O., Bhatia, S., Terheyden, P., D’Angelo, S. P., Shih, K. C., Lebbé, C., Milella, M., Brownell, I., Lewis, K. D., Lorch, J. H., von Heydebreck, A., Hennessy, M., & Nghiem, P. (2018). Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-017-0310-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.